{"disease":{"id":"biologics","name":"biologics"},"drugs":{"marketed":[{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05205603","title":"Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":438,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT07126015","title":"Predicting Biologic Therapy Success in Ulcerative Colitis Using Intestinal Ultrasound and Fat Assessment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05642247","title":"Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT07475052","title":"Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT07149792","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT04032756","title":"Tofacitinib Registry of Patients With Ulcerative Colitis in Germany","phase":"","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Ced Service GmbH","has_results":false},{"nct_id":"NCT07362693","title":"A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}